Literature DB >> 16773410

Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome.

Bethany J Foster1, Justine Shults, Babette S Zemel, Mary B Leonard.   

Abstract

The objective of this work was to determine the prevalence of obesity, defined as BMI >95th percentile, in children treated with glucocorticoids for steroid-sensitive nephrotic syndrome (SSNS), and to identify risk factors for the development for glucocorticoid-induced obesity. The experimental design involved a cross-sectional study of 96 individuals (4 to 21 yrs) treated with glucocorticoids for SSNS and 186 healthy reference subjects. Logistic regression was used to generate odds ratios for obesity. Glucocorticoid exposure was classified as recent in the 54 subjects treated with glucocorticoids in the prior six months, and remote in the remaining 42 subjects. Recent exposure was associated with significantly increased odds of obesity [odds ratio (95% CI): 26.14 (7.54, 90.66)] in non-blacks only. Each one-unit increase in maternal BMI was associated with a 35% increase in the odds of obesity in recent SSNS subjects (p=0.003). The effect of maternal BMI on the odds of obesity was significantly greater in recent SSNS subjects than in reference subjects (test for interaction p=0.038). The odds of obesity were also significantly increased [odds ratio 5.22 (1.77, 15.41), p=0.003] in all subjects with remote glucocorticoid exposure (black and non-black). These results indicate that non-black race and increased maternal BMI are risk factors for glucocorticoid-induced obesity in subjects with recent exposure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773410     DOI: 10.1007/s00467-006-0100-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  18 in total

1.  Predicting obesity in young adulthood from childhood and parental obesity.

Authors:  R C Whitaker; J A Wright; M S Pepe; K D Seidel; W H Dietz
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

2.  Body mass index in primary and secondary pediatric hypertension.

Authors:  Renee F Robinson; Donald L Batisky; John R Hayes; Milap C Nahata; John D Mahan
Journal:  Pediatr Nephrol       Date:  2004-12       Impact factor: 3.714

3.  CDC growth charts: United States.

Authors:  R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson
Journal:  Adv Data       Date:  2000-06-08

4.  Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children.

Authors: 
Journal:  J Pediatr       Date:  1979-08       Impact factor: 4.406

5.  Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids.

Authors:  Bethany J Foster; Justine Shults; Babette S Zemel; Mary B Leonard
Journal:  Am J Clin Nutr       Date:  2004-11       Impact factor: 7.045

6.  Optimising nutrition in chronic renal insufficiency--growth.

Authors:  Lisa J Norman; Ian A Macdonald; Alan R Watson
Journal:  Pediatr Nephrol       Date:  2004-09-14       Impact factor: 3.714

7.  The LMS method for constructing normalized growth standards.

Authors:  T J Cole
Journal:  Eur J Clin Nutr       Date:  1990-01       Impact factor: 4.016

8.  A simple estimate of glomerular filtration rate in adolescent boys.

Authors:  G J Schwartz; B Gauthier
Journal:  J Pediatr       Date:  1985-03       Impact factor: 4.406

9.  Prevalence and trends in overweight among US children and adolescents, 1999-2000.

Authors:  Cynthia L Ogden; Katherine M Flegal; Margaret D Carroll; Clifford L Johnson
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

10.  Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome.

Authors:  R Tanaka; N Yoshikawa; Y Kitano; H Ito; H Nakamura
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

View more
  9 in total

1.  Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome.

Authors:  Akio Nakamura; Ryo Niimi; Kumiko Kurosaki; Yukishige Yanagawa
Journal:  Clin Exp Nephrol       Date:  2010-07-17       Impact factor: 2.801

2.  Obesity and other clinical endpoints in steroid-sensitive nephrotic syndrome.

Authors:  Thomas J Neuhaus; Eva-Maria Rüth; Markus Kemper
Journal:  Pediatr Nephrol       Date:  2006-12-07       Impact factor: 3.714

3.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy.

Authors:  Yoshitsugu Kaku; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Kenji Ishikura; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.801

4.  Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases.

Authors:  Natalie J Shiff; Rollin Brant; Jaime Guzman; David A Cabral; Adam M Huber; Paivimm Miettunen; Johannes Roth; Rosie Scuccimarri; Nathalie Alos; Stephanie A Atkinson; Jean Paul Collet; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Bianca Lang; Maggie Larche; Claire Leblanc; Celia Rodd; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Frank Rauch; Leanne M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-01       Impact factor: 4.794

5.  The long-term outcome of childhood nephrotic syndrome in Germany: a cross-sectional study.

Authors:  Malik Aydin; Ingo Franke; Lisa Kurylowicz; Rainer Ganschow; Michael Lentze; Mark Born; Rebekka Hagemann
Journal:  Clin Exp Nephrol       Date:  2019-02-05       Impact factor: 2.801

6.  Long-term obesity prevalence and linear growth in children with idiopathic nephrotic syndrome: is normal growth and weight control possible with steroid-sparing drugs and low-dose steroids for relapses?

Authors:  Nilüfer Göknar; Hazel Webb; Aoife Waters; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2021-11-12       Impact factor: 3.651

7.  Effect of obesity on response to cardiovascular drugs in pediatric patients with renal disease.

Authors:  Sherif Hanafy; Maury Pinsk; Fakhreddin Jamali
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

8.  Subclinical cardiovascular disease and its association with risk factors in children with steroid-resistant nephrotic syndrome.

Authors:  Cengiz Candan; Nur Canpolat; Selman Gökalp; Nurdan Yıldız; Pınar Turhan; Mehmet Taşdemir; Lale Sever; Salim Çalışkan
Journal:  Pediatr Nephrol       Date:  2013-09-15       Impact factor: 3.714

Review 9.  Treating the idiopathic nephrotic syndrome: are steroids the answer?

Authors:  Georges Deschênes; Claire Dossier; Julien Hogan
Journal:  Pediatr Nephrol       Date:  2018-06-04       Impact factor: 3.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.